ABUS vs EIX
Arbutus Biopharma Corp (ABUS) versus Edison International (EIX) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Edison International (EIX) is a utilities - regulated electric company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported EIX revenue for 2024-12-31 was $17.60B. Net income was $1.55B. Revenue was up 7.7% from 2023-12-31 to 2024-12-31. EIX currently screens at market cap $19.73B and trailing P/E 7.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. EIX currently screens at market cap $19.73B and trailing P/E 7.3.
Not investment advice. Open the ABUS and EIX stock pages for the full models.
Not investment advice.